Ameriprise’s ProKidney PROK Stock Holding History

Ameriprise’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11,388	Closed	-$9.98K	–	4095
2025 Q1	$9.98K	Buy	11,388 +69	+0.6%	+$96	﹤0.01%	4003
2024 Q4	$19.1K	Buy	+11,319	New	+$20.4K	﹤0.01%	4054

Other funds holding PROK

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brown University Providence, Rhode Island $102M AUM 26.79% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ameriprise's PROK Position: Q2 2025 in Review

Ameriprise sold out of ProKidney (PROK) in Q2 2025, closing a stake of 11,388 shares — an estimated $9.98K sold.

Ameriprise first reported a position in PROK in Q4 2024 and held it in 2 quarters. The position peaked at $19.1K in Q4 2024. 56 funds tracked by Wall St. Rank hold PROK as of Q2 2025.

Ameriprise reported no remaining ProKidney position as of Q2 2025 after selling out during the quarter.
Ameriprise sold 11,388 ProKidney shares in Q2 2025, an estimated $9.98K.
Ameriprise first reported a position in ProKidney in Q4 2024 and held it in 2 quarters.
Ameriprise's ProKidney position peaked at $19.1K in Q4 2024.
56 funds tracked by Wall St. Rank held ProKidney as of Q2 2025.

Based on Ameriprise's 13F filing for Q2 2025, filed 14 Aug 2025.